290 articles in this topic
A 5-year cohort study finds that CGM-derived time in range predicts arterial stiffness changes independently of HbA1c in type 2 diabetes.
Emerging evidence suggests GLP-1 receptor agonists like semaglutide may reduce cocaine craving and relapse by dampening dopamine signaling.
A large retrospective study finds GLP-1 receptor agonists significantly reduce AMD risk in both diabetic and obese patients.
A 10-year Korean cohort study finds GLP-1 receptor agonists don't raise psychiatric risk compared to DPP-4 inhibitors, but show modest signals vs SGLT2 inhibitors.
A traditional Chinese formula and its key compound GsRg1 restore brain insulin signaling in obese rats by activating hypothalamic self-cleaning pathways.
A large real-world study finds GLP-1 drugs cut anxiety and depression risk vs. older weight-loss meds — but tirzepatide raises insomnia flags.
A 30-week Pakistani multicentre study shows biosynthetic semaglutide delivers clinically meaningful glycemic and weight benefits in routine care.
New research shows chronic semaglutide treatment causes weight loss while leaving taste perception fully intact, pointing to motivational rather than sensory mechanisms.
A real-world study of 549 patients finds that combining GLP-1 receptor agonists with SGLT-2 inhibitors meaningfully improves glucose control — and baseline HbA1c predicts who benefits most.
A massive international meta-analysis of 25 cohorts finds higher BMI consistently reduces fracture risk, prompting updates to the FRAX risk tool.
New validated analytical method quantifies fentanyl, morphine, buprenorphine, and three other opioids simultaneously in both plasma and oral fluid.
A mouse study reveals how aging and poor diet synergistically disrupt liver thyroid hormone metabolism, accelerating fatty liver disease — and why resmetirom may help.
